文献速递肾小球疾病

伏环孢素对伴大量蛋白尿的增殖性狼疮肾炎的疗效

Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-12-18

该分析基于3期研究亚组,纳入148例III或IV型(±V型)狼疮肾炎且基线UPCR≥3 g/g的成人患者,随机接受伏环孢素(23.7 mg每日两次)或安慰剂,均联用MMF和低剂量糖皮质激素治疗12个月。伏环孢素组完全肾脏缓解率显著更高(34% vs 11%,OR 4.43,95%CI 1.78至>9.99,P=0.001),且UPCR≤0.5 g/g达标更早(HR 2.07,95%CI 1.19至3.60,P=0.01),安全性相似。

要点

  • 伏环孢素联合MMF和低剂量激素显著提高完全肾脏缓解率。
  • 伏环孢素组UPCR≤0.5 g/g达标更早,部分缓解率无显著差异。
  • 两组不良事件发生率相似,eGFR保持稳定。

核心结论

  • 在增殖性狼疮肾炎伴大量蛋白尿患者中,伏环孢素联合MMF和低剂量糖皮质激素显著提高完全肾脏缓解率并更早降低蛋白尿,且不增加不良事件。

研究设计与样本

  • 3期研究的事后亚组分析,纳入148例III或IV型(±V型)狼疮肾炎且基线UPCR≥3 g/g的成人患者,随机接受口服伏环孢素23.7 mg每日两次(n=76)或安慰剂(n=72)治疗12个月,均联用MMF和低剂量糖皮质激素。

主要发现

  • 12个月时伏环孢素组完全肾脏缓解率为34%,对照组为11%(OR 4.43,95%CI 1.78至>9.99,P=0.001)。
  • 12个月时伏环孢素组部分肾脏缓解率为65%,对照组为51%(OR 1.60,95%CI 0.8至3.20,P=0.18)。
  • 伏环孢素组51%的患者达到UPCR≤0.5 g/g,对照组为26%,且伏环孢素组达标时间显著更早(HR 2.07,95%CI 1.19至3.60,P=0.01)。
  • 两组不良事件发生率相似,平均eGFR值保持稳定且在正常范围内。

关键数值与推荐

  • 完全肾脏缓解定义为UPCR≤0.5 g/g且eGFR稳定、使用低剂量糖皮质激素且未使用挽救药物。
  • 部分肾脏缓解定义为UPCR较基线下降≥50%。

临床怎么用

  • 对于增殖性狼疮肾炎伴基线UPCR≥3 g/g的患者,可考虑在MMF和低剂量糖皮质激素基础上加用伏环孢素以提高完全肾脏缓解率并加速蛋白尿下降。

局限性

  • 该分析为3期研究的亚组分析,样本量有限(148例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a phase 3 study of adults with active lupus nephritis, addition of voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids led to significant improvements in the proportion of participants achieving complete and partial renal response as well as sustained reduction in proteinuria. This analysis examined the efficacy and safety of voclosporin in a subgroup of the phase 3 study with proliferative lupus nephritis and high levels of proteinuria. METHODS: Participants were randomized to oral voclosporin (23.7 mg twice daily) or placebo for 12 months; all participants received MMF and low-dose glucocorticoids. This analysis includes participants with class III or IV (±class V) lupus nephritis and baseline urine protein-creatinine ratio (UPCR) ≥3 g/g. Efficacy end points included complete renal response (UPCR ≤0.5 g/g with stable eGFR, low-dose glucocorticoids, and no rescue medication), partial renal response (≥50% reduction from baseline UPCR), and UPCR over time. Safety outcomes were also assessed. RESULTS: A total of 148 participants were in the voclosporin ( n =76) and control ( n =72) arms. At 12 months, 34% and 11% of participants in the voclosporin and control arms, respectively, achieved a complete renal response (odds ratio, 4.43; 95% confidence interval [CI], 1.78 to >9.99; P = 0.001). A partial renal response was achieved by 65% of the voclosporin arm and 51% of the control arm at 12 months (odds ratio, 1.60; 95% CI, 0.8 to 3.20; P = 0.18). More voclosporin- than control-treated participants achieved UPCR ≤0.5 g/g (51% versus 26%), and voclosporin-treated participants met this end point significantly earlier (hazard ratio, 2.07; 95% CI, 1.19 to 3.60; P = 0.01). The incidence of adverse events was similar between the arms; mean eGFR values remained stable and within normal range in both arms. CONCLUSIONS: Addition of voclosporin to MMF and low-dose glucocorticoids resulted in a significantly higher proportion of participants with proliferative lupus nephritis achieving complete and partial renal responses as well as earlier reductions in proteinuria, with no evidence of worsening kidney function.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Menn-Josephy H, Hodge LS, Birardi V, et al. Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria. Clin J Am Soc Nephrol. 2023. PMID: 38110196. doi:10.2215/CJN.0000000000000297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。